Cei mai mulţi dintre pacienţii care dezvoltă un al doilea sau al treilea cancer o fac în intervalul 2-5 ani, ceea ce impune un screening adecvat în această perioadă.

Deşi costurile sunt ridicate, testarea genetică a pacienţilor care dezvoltă tumora secundam ar putea contribui la un diagnostic precoce sau chiar la evitarea dezvoltării tumorii terţe, dar, mai important decât atât, ar putea oferi un sfat genetic important familiei.

BIBLIOGRAFIE

1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M et al. Global surveillance of trends în cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries în 71 countries. *Lancet*. 2018;391(10125):1076-1084.
2. Masvidal Calpe R, Codina Cazador A, Farrés Coll R, Alcobilla Ferrara E, Gómez Castella F, Gironés Vila J. Synchronous colonic and rectal carcinomas. *Rev Esp Enferm Dig.* 1993;84(4):231–4.
3. Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ et al. Risk of metachronous colon cancer following surgery for rectal cancer în mismatch repair gene mutation carriers. *Ann Surg Oncol.* 2013; 20(6):1829-36.
4. Testori A, Cioffi U, De Simone M, Bini F, Vaghi A, Lemos AA et al. Multiple primary synchronous malignant tumors. *BMC Res Notes.* 2015; 15(04) 1724-5.
5. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T. Multiple primary cancer: An experience at the Cancer Institute Hospital with special reference to colorectal cancer. *Int J Clin Oncol.* 2003; 8(3):162-167.
6. Ng AK, Travis LB. Subsequent malignant neoplasms în cancer survivors. *Cancer J.* 2008; 14(6):429-34.
7. Syngal S. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations în MSH2 and MLH1. *J Med Genet.* 2000; 37(9):641-5.
8. Talley A. NCCN Clinical Practice Guidelines în Oncology (NCCN Guidelines®) Pancreatic Adenocarcinoma. *Pancreas*. 2013; 32(1):74-85.
9. Uk CR. Worldwide cancer statistics. *Cancer research UK.* 2014. 9:572-584.
10. Moertel CG. Adenocarcinoma of unknown origin. *Annals of Internal Medicine.* 1979; 91(4):646-647.
11. Moertel CG. Incidence and significance of multiple primary malignant neoplasms. *Ann N Y Acad Sci.* 1964;114(2):886-895.
12. Billroth T. Pathology and therapeutics, în fifty lectures. 1871. *Clin Orthop Relat Res.* 2003; 408(408):4-11.
13. Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer în familial adenomatous polyposis. *Lancet*, 1988;331(8595):1149-1151.
14. Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of Microsatellite instability and favorable prognosis. *Am J Surg Pathol.* 2013; 37(11):1660-70.
15. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T et al. Multiple primary tumours: Challenges and approaches, a review. *ESMO Open.* 2017. 2(2):172-175.
16. Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks în Crohn disease patients. *Ann Oncol.* 2009;20(3):574–580.
17. M'Koma AE. Inflammatory bowel disease: An expanding global health problem. Clinical Medicine Insights: *Gastroenterology*. 2013. 14(6):33-47.
18. Stidham RW, Higgins PDR. Colorectal cancer în inflammatory bowel disease. *Clin Colon Rectal Surg*. 2018; 31(03):168-178.
19. Amersi F, Agustin M, Ko CY. Colorectal cancer: Epidemiology, risk factors, and health services. *Clinics în Colon and Rectal Surgery.* 2005;18(3):133-40.
20. Wells K, Wise PE. Hereditary Colorectal Cancer Syndromes. *Surgical Clinics of North America*. 2017. 97(3):605-625.
21. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL et al. Cancer susceptibility gene mutations în individuals with colorectal cancer. *J Clin Oncol.* 2017; 35(10):1086-1095.
22. Munck A, Gargouri L, Alberti C, Viala J, Peuchmaur M, Lenaerts C et al. Evaluation of guidelines for management of familial adenomatous polyposis în a multicenter pediatric cohort. *J Pediatr Gastroenterol Nutr.* 2011; 53(3):296-302.
23. Beggs AD, Latchford AR, Vasen HFA, Moslein G, Alonso A, Aretz S et al. Peutz - Jeghers syndrome: A systematic review and recommendations for management. *Gut*. 2010 Jul;59(7):975-86.
24. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: The advantage of more extensive colon surgery. *Gut*. 2011; 60 (7) 950-957.
25. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barberá VM, González S et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. *Eur J Cancer.* 2014; 50(13):2241-50.
26. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. *J Gastrointest Oncol.* 2012; 3(3):153-73.
27. Rex DK. Optimal withdrawal and examination în colonoscopy. Gastroenterology Clinics of North America. 2013. 42(3):429-42.